Should glucose screening be repeated for large-for-gestational-age fetuses in the third trimester of non-diabetic pregnancies? A scoping review.
- 1Universidade Federal de Minas Gerais Faculdade de Medicina Belo HorizonteMG Brazil Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
- 2Universidade Federal de Minas Gerais Hospital das Clínicas Belo HorizonteMG Brazil Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Abstract
Objective
To map and synthesize global evidence regarding the clinical utility, diagnostic yield, and perinatal impact of repeating third-trimester glucose screening in previously screen-negative, non-diabetic pregnancies complicated by ultrasound-suspected large-for-gestational-age (LGA) fetuses or macrosomia, evaluating whether late dysglycemia explains accelerated growth.Methods
Following defined criteria for singleton pregnancies with normal mid-trimester testing and late-onset suspected fetal overgrowth, a systematic search was performed in June 2026 across PubMed, Embase, and SciELO for peer-reviewed articles in English, Portuguese, and Spanish. Two independent reviewers handled selection, rigorous critical appraisal, and data extraction for qualitative narrative synthesis.Results
Fifteen observational studies met inclusion criteria (nine retrospective cohorts, four prospective cohorts, two case-controls). Diagnostic yield for late-onset gestational diabetes mellitus (GDM) ranged from 2.9% to 24.6%. Diagnosing late GDM consistently changed clinical management, driving higher rates of labor induction and cesarean deliveries. Active standard-of-care maternal interventions initiated after retesting effectively curtailed excessive growth trajectories, producing no statistically significant differences in acute neonatal morbidities, such as shoulder dystocia or neonatal intensive care unit admissions, compared to non-diabetic controls.Conclusion
Indiscriminate repeat third-trimester glucose testing for isolated LGA fetuses cannot be routinely recommended due to high methodological heterogeneity and no randomized controlled trials (RCTs). Fetal overgrowth remains predominantly multifactorial, mediated by maternal obesity and dyslipidemia. Clinical management warrants careful individualization, and robust interventional RCTs are needed.Open science framework
https://doi.org/10.17605/OSF.IO/TFH7A.
Related
- Mid-Trimester Cervical Length Screening in Routine Practice: Short-Cervix Prevalence, Preterm Birth and the Shift of the Progesterone Counselling Threshold from 20 to 25 mm in a 15-Year Single-Centre Cohort of 20,168 Singleton Pregnancies
- Maternal Recognition of Ultrasound-Observed Fetal Movements Among Pregnancies in the Third Trimester: Concordance, Directional Discrepancies, and Associated Factors
- A machine learning-based predictive model for gestational diabetes mellitus based on first trimester clinical indicators
- Second-trimester fetal thymic-thoracic ratio in pregnancies treated with levothyroxine for elevated first-trimester TSH: a retrospective case-control study
- Developmental Programming and Epigenetic Inheritance in Diabetic Pregnancies: Unraveling an Intergenerational Burden
BibTeX
@article{leal2026should,
title = {{Should glucose screening be repeated for large-for-gestational-age fetuses in the third trimester of non-diabetic pregnancies? A scoping review.}},
author = {Caio Ribeiro Vieira Leal and Mário Dias Corrêa},
journal = {Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia},
year = {2026},
month = oct,
doi = {10.61622/rbgo/2026rbgo76},
url = {https://europepmc.org/article/MED/43017594},
note = {CC BY},
}
RIS
TY - JOUR
TI - Should glucose screening be repeated for large-for-gestational-age fetuses in the third trimester of non-diabetic pregnancies? A scoping review.
AU - Caio Ribeiro Vieira Leal
AU - Mário Dias Corrêa
PY - 2026
DA - 2026/10/30
JO - Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia
DO - 10.61622/rbgo/2026rbgo76
UR - https://europepmc.org/article/MED/43017594
AB - Objective To map and synthesize global evidence regarding the clinical utility, diagnostic yield, and perinatal impact of repeating third-trimester glucose screening in previously screen-negative, non-diabetic pregnancies complicated by ultrasound-suspected large-for-gestational-age (LGA) fetuses or macrosomia, evaluating whether late dysglycemia explains accelerated growth.Methods Following defined criteria for singleton pregnancies with normal mid-trimester testing and late-onset suspected fetal overgrowth, a systematic search was performed in June 2026 across PubMed, Embase, and SciELO for peer-reviewed articles in English, Portuguese, and Spanish. Two independent reviewers handled selection, rigorous critical appraisal, and data extraction for qualitative narrative synthesis.Results Fifteen observational studies met inclusion criteria (nine retrospective cohorts, four prospective cohorts, two case-controls). Diagnostic yield for late-onset gestational diabetes mellitus (GDM) ranged from 2.9% to 24.6%. Diagnosing late GDM consistently changed clinical management, driving higher rates of labor induction and cesarean deliveries. Active standard-of-care maternal interventions initiated after retesting effectively curtailed excessive growth trajectories, producing no statistically significant differences in acute neonatal morbidities, such as shoulder dystocia or neonatal intensive care unit admissions, compared to non-diabetic controls.Conclusion Indiscriminate repeat third-trimester glucose testing for isolated LGA fetuses cannot be routinely recommended due to high methodological heterogeneity and no randomized controlled trials (RCTs). Fetal overgrowth remains predominantly multifactorial, mediated by maternal obesity and dyslipidemia. Clinical management warrants careful individualization, and robust interventional RCTs are needed.Open science framework https://doi.org/10.17605/OSF.IO/TFH7A.
SN - 0100-7203
SN - 1806-9339
ER -